Reply to Tjalma, W.A. Comment on “Gentile et al. Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. Cancers 2025, 17, 766”
Damiano Gentile(Humanitas University), Corrado Tinterri(Humanitas University), Simone Di Maria Grimaldi(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), E. Barbieri(IRCCS Humanitas Research Hospital), Jacopo Canzian(Humanitas University)
Cited by 0
Related Papers
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial
|Annals of Surgical Oncology|2022|162
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150